Dr Gulietta Pupo

Level A Research Only
Medicine, Westmead Clinical School

Telephone +61 2 9845 9052
Fax +61 2 9845 9102

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Gallagher, S., Mijatov, B., Gunatilake, D., Gowrishankar, K., Tiffen, J., James, W., Jin, L., Pupo, G., Cullinane, C., McArthur, G., Rizos, H., Hersey, P., et al (2014). Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell & Melanoma Research, 27(6), 1126-1137. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Gallagher, S., Mijatov, B., Gunatilake, D., Tiffen, J., Gowrishankar, K., Jin, L., Pupo, G., Cullinane, C., Prinjha, R., Smithers, N., Rizos, H., Hersey, P., et al (2014). The Epigenetic Regulator I-BET151 Induces BIM Dependent Apoptosis and Cell Cycle Arrest OF Human Melanoma Cells. Journal of Investigative Dermatology, 134(11), 1523-1747. [More Information]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell & Melanoma Research, 26(6), 852-860. [More Information]
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • Fung, C., Pupo, G., Scolyer, R., Kefford, R., Rizos, H. (2013). p16INK4a deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell & Melanoma Research, 26(2), 236-246. [More Information]
  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Zhou, L., Pupo, G., Gupta, P., Liu, B., Tran, S., Rahme, R., Wang, B., Rua, R., Rizos, H., Carroll, A., Saksena, N., et al (2012). A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics, 13(November), 1-17. [More Information]
  • Gowrishankar, K., Snoyman, S., Pupo, G., Becker, T., Kefford, R., Rizos, H. (2012). Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. Journal of Investigative Dermatology, 132(7), 1850-1859. [More Information]
  • Kim, J., McCarthy, S., Thompson, J., Pupo, G., Vonthethoff, L., Nash, P., Mann, G., Scolyer, R. (2012). Cellular blue naevus involving the urinary bladder. Pathology, 44(7), 664-668. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Kefford, R., Long, G., et al (2012). Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2(5), 414-424. [More Information]
  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]
  • Wong, E., Tesoriero, A., Pupo, G., Mann, G., KConFab, C., ABCFS, T., McCredie, M., Giles, G., Hopper, J., Hopper, G., et al (2008). Is MSH2 a breast cancer susceptibility gene? Familial Cancer, 7(2), 151-155. [More Information]
  • Lose, F., Arnold, J., Young, D., Brown, C., Mann, G., Pupo, G., Khanna, K., Chenevix-Trench, G., Spurdle, A. (2007). BCoR-L1 variation and breast cancer. Breast Cancer Research, 9(4), 1-12. [More Information]
  • Marsh, A., Healey, S., Lewis, A., Spurdle, A., Kedda, M., Khanna, K., Mann, G., Pupo, G., Lakhani, S., Chenevix-Trench, G. (2007). Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Research and Treatment, 105(3), 377-389. [More Information]
  • Mann, G., Pupo, G., Newman, B., Chenevix-Trench, G., McGuffog, L., Southey, M., Easton, D., Szabo, C., Renard, H., Odefrey, F., et al (2006). A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 45(7). [More Information]
  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Lose, F., Lovelock, P., Chenevix-Trench, G., Mann, G., Pupo, G., Spurdle, A. (2006). Variation in the RAD51 gene and familial breast cancer. Breast Cancer Research, 8(3), R26-R26. [More Information]
  • Lewis, A., Flanagan, J., Marsh, A., Pupo, G., Mann, G., Spurdle, A., Lindeman, G., Visvader, J., Brown, M., Chenevix-Trench, G., et al (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005-R1016. [More Information]
  • Chenevix-Trench, G., Spurdle, A., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M., Pupo, G., Kirk, J., Tucker, P., Mann, G., et al (2002). Dominant Negative ATM Mutations in Breast Cancer Families. Journal of the National Cancer Institute, 94(3), 205-215.
  • Marsh, A., Spurdle, A., Turner, B., Fereday, S., Thorne, H., Pupo, G., Mann, G., Hopper, J., Sambrook, J., Chenevix-Trench, G., et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 3(5), 346-349.

2014

  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Gallagher, S., Mijatov, B., Gunatilake, D., Gowrishankar, K., Tiffen, J., James, W., Jin, L., Pupo, G., Cullinane, C., McArthur, G., Rizos, H., Hersey, P., et al (2014). Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell & Melanoma Research, 27(6), 1126-1137. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Becker, T., Boyd, S., Mijatov, B., Gowrishankar, K., Snoyman, S., Pupo, G., Scolyer, R., Mann, G., Kefford, R., Zhang, X., Rizos, H. (2014). Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene, 33(9), 1158-1166. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Parmenter, T., Kleinschmidt, M., Kinross, K., Bond, S., Li, J., Kaadige, M., Rao, A., Sheppard, K., Hugo, W., Pupo, G., Long, G., Scolyer, R., Rizos, H., et al (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discovery, 4(4), 423-433. [More Information]
  • Gallagher, S., Mijatov, B., Gunatilake, D., Tiffen, J., Gowrishankar, K., Jin, L., Pupo, G., Cullinane, C., Prinjha, R., Smithers, N., Rizos, H., Hersey, P., et al (2014). The Epigenetic Regulator I-BET151 Induces BIM Dependent Apoptosis and Cell Cycle Arrest OF Human Melanoma Cells. Journal of Investigative Dermatology, 134(11), 1523-1747. [More Information]

2013

  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell & Melanoma Research, 26(6), 852-860. [More Information]
  • Boyd, S., Mijatov, B., Pupo, G., Tran, S., Gowrishankar, K., Shaw, H., Goding, C., Scolyer, R., Mann, G., Kefford, R., Rizos, H., Becker, T. (2013). Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. Journal of Investigative Dermatology, 133(5), 1269-1277. [More Information]
  • Fung, C., Pupo, G., Scolyer, R., Kefford, R., Rizos, H. (2013). p16INK4a deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell & Melanoma Research, 26(2), 236-246. [More Information]

2012

  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Zhou, L., Pupo, G., Gupta, P., Liu, B., Tran, S., Rahme, R., Wang, B., Rua, R., Rizos, H., Carroll, A., Saksena, N., et al (2012). A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics, 13(November), 1-17. [More Information]
  • Gowrishankar, K., Snoyman, S., Pupo, G., Becker, T., Kefford, R., Rizos, H. (2012). Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. Journal of Investigative Dermatology, 132(7), 1850-1859. [More Information]
  • Kim, J., McCarthy, S., Thompson, J., Pupo, G., Vonthethoff, L., Nash, P., Mann, G., Scolyer, R. (2012). Cellular blue naevus involving the urinary bladder. Pathology, 44(7), 664-668. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Kefford, R., Long, G., et al (2012). Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2(5), 414-424. [More Information]

2010

  • Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. Genes Chromosomes and Cancer, 49(12), 1082-1094. [More Information]
  • Scurr, L., Pupo, G., Becker, T., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R., Mann, G., Becker, J., Kefford, R., Rizos, H. (2010). IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence. Cell, 141(4), 717-727. [More Information]

2008

  • Wong, E., Tesoriero, A., Pupo, G., Mann, G., KConFab, C., ABCFS, T., McCredie, M., Giles, G., Hopper, J., Hopper, G., et al (2008). Is MSH2 a breast cancer susceptibility gene? Familial Cancer, 7(2), 151-155. [More Information]

2007

  • Lose, F., Arnold, J., Young, D., Brown, C., Mann, G., Pupo, G., Khanna, K., Chenevix-Trench, G., Spurdle, A. (2007). BCoR-L1 variation and breast cancer. Breast Cancer Research, 9(4), 1-12. [More Information]
  • Marsh, A., Healey, S., Lewis, A., Spurdle, A., Kedda, M., Khanna, K., Mann, G., Pupo, G., Lakhani, S., Chenevix-Trench, G. (2007). Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Research and Treatment, 105(3), 377-389. [More Information]

2006

  • Mann, G., Pupo, G., Newman, B., Chenevix-Trench, G., McGuffog, L., Southey, M., Easton, D., Szabo, C., Renard, H., Odefrey, F., et al (2006). A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 45(7). [More Information]
  • Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 8(1), 1-15. [More Information]
  • Lose, F., Lovelock, P., Chenevix-Trench, G., Mann, G., Pupo, G., Spurdle, A. (2006). Variation in the RAD51 gene and familial breast cancer. Breast Cancer Research, 8(3), R26-R26. [More Information]

2005

  • Lewis, A., Flanagan, J., Marsh, A., Pupo, G., Mann, G., Spurdle, A., Lindeman, G., Visvader, J., Brown, M., Chenevix-Trench, G., et al (2005). Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 7(6), R1005-R1016. [More Information]

2002

  • Chenevix-Trench, G., Spurdle, A., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M., Pupo, G., Kirk, J., Tucker, P., Mann, G., et al (2002). Dominant Negative ATM Mutations in Breast Cancer Families. Journal of the National Cancer Institute, 94(3), 205-215.

2001

  • Marsh, A., Spurdle, A., Turner, B., Fereday, S., Thorne, H., Pupo, G., Mann, G., Hopper, J., Sambrook, J., Chenevix-Trench, G., et al (2001). The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 3(5), 346-349.

To update your profile click here. For support on your academic profile contact .